Ghent University Academic Bibliography

Advanced

The ReNAissanCe of mRNA-based cancer therapy

Sandra Van Lint UGent, Dries Renmans, Katrijn Broos, Heleen Dewitte UGent, Ine Lentacker UGent, Carlo Heirman, Karine Breckpot and Kris Thielemans (2015) EXPERT REVIEW OF VACCINES. 14(2). p.235-251
abstract
About 25 years ago, mRNA became a tool of interest in anticancer vaccination approaches. However, due to its rapid degradation in situ, direct application of mRNA was confronted with considerable skepticism during its early use. Consequently, mRNA was for a long time mainly used for the ex vivo transfection of dendritic cells, professional antigen-presenting cells known to stimulate immunity. The interest in direct application of mRNA experienced a revival, as researchers became aware of the many advantages mRNA offers. Today, mRNA is considered to be an ideal vehicle for the induction of strong immune responses against cancer. The growing numbers of preclinical trials and as a consequence the increasing clinical application of mRNA as an off-the-shelf anticancer vaccine signifies a renaissance for transcript-based antitumor therapy. In this review, we highlight this renaissance using a timeline providing all milestones in the application of mRNA for anticancer vaccination.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
FLT3 LIGAND, IN-VIVO, LENGTH TUMOR-ANTIGENS, CYTOTOXIC T-LYMPHOCYTES, DENDRITIC CELL VACCINATION, dendritic cell, cancer, immunotherapy, COLONY-STIMULATING FACTOR, vaccine, MELANOMA PATIENTS, ANTITUMOR IMMUNITY, DIRECT-INJECTION, CTL RESPONSES
journal title
EXPERT REVIEW OF VACCINES
Expert Rev. Vaccines
volume
14
issue
2
issue title
Special focus: mRNA vaccines
pages
235 - 251
Web of Science type
Review
Web of Science id
000350053200009
JCR category
IMMUNOLOGY
JCR impact factor
4.222 (2015)
JCR rank
41/150 (2015)
JCR quartile
2 (2015)
ISSN
1476-0584
DOI
10.1586/14760584.2015.957685
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
5875658
handle
http://hdl.handle.net/1854/LU-5875658
date created
2015-03-05 12:00:57
date last changed
2016-12-19 15:46:44
@article{5875658,
  abstract     = {About 25 years ago, mRNA became a tool of interest in anticancer vaccination approaches. However, due to its rapid degradation in situ, direct application of mRNA was confronted with considerable skepticism during its early use. Consequently, mRNA was for a long time mainly used for the ex vivo transfection of dendritic cells, professional antigen-presenting cells known to stimulate immunity. The interest in direct application of mRNA experienced a revival, as researchers became aware of the many advantages mRNA offers. Today, mRNA is considered to be an ideal vehicle for the induction of strong immune responses against cancer. The growing numbers of preclinical trials and as a consequence the increasing clinical application of mRNA as an off-the-shelf anticancer vaccine signifies a renaissance for transcript-based antitumor therapy. In this review, we highlight this renaissance using a timeline providing all milestones in the application of mRNA for anticancer vaccination.},
  author       = {Van Lint, Sandra and Renmans, Dries and Broos, Katrijn and Dewitte, Heleen and Lentacker, Ine and Heirman, Carlo and Breckpot, Karine and Thielemans, Kris},
  issn         = {1476-0584},
  journal      = {EXPERT REVIEW OF VACCINES},
  keyword      = {FLT3 LIGAND,IN-VIVO,LENGTH TUMOR-ANTIGENS,CYTOTOXIC T-LYMPHOCYTES,DENDRITIC CELL VACCINATION,dendritic cell,cancer,immunotherapy,COLONY-STIMULATING FACTOR,vaccine,MELANOMA PATIENTS,ANTITUMOR IMMUNITY,DIRECT-INJECTION,CTL RESPONSES},
  language     = {eng},
  number       = {2},
  pages        = {235--251},
  title        = {The ReNAissanCe of mRNA-based cancer therapy},
  url          = {http://dx.doi.org/10.1586/14760584.2015.957685},
  volume       = {14},
  year         = {2015},
}

Chicago
Van Lint, Sandra, Dries Renmans, Katrijn Broos, Heleen Dewitte, Ine Lentacker, Carlo Heirman, Karine Breckpot, and Kris Thielemans. 2015. “The ReNAissanCe of mRNA-based Cancer Therapy.” Expert Review of Vaccines 14 (2): 235–251.
APA
Van Lint, S., Renmans, D., Broos, K., Dewitte, H., Lentacker, I., Heirman, C., Breckpot, K., et al. (2015). The ReNAissanCe of mRNA-based cancer therapy. EXPERT REVIEW OF VACCINES, 14(2), 235–251.
Vancouver
1.
Van Lint S, Renmans D, Broos K, Dewitte H, Lentacker I, Heirman C, et al. The ReNAissanCe of mRNA-based cancer therapy. EXPERT REVIEW OF VACCINES. 2015;14(2):235–51.
MLA
Van Lint, Sandra, Dries Renmans, Katrijn Broos, et al. “The ReNAissanCe of mRNA-based Cancer Therapy.” EXPERT REVIEW OF VACCINES 14.2 (2015): 235–251. Print.